

# In Vivo and in Vitro Synthesis of Phosphatidylglycerol by an *Escherichia coli* Cardiolipin Synthase<sup>\*[5]</sup>

Received for publication, October 5, 2016, and in revised form, October 18, 2016 Published, JBC Papers in Press, October 19, 2016, DOI 10.1074/jbc.M116.762070

Chijun Li, Brandon K. Tan, Jinshi Zhao, and Ziqiang Guan<sup>1</sup>

From the Department of Biochemistry, Duke University Medical Center, Durham, North Carolina 27710

Edited by George Carman

Phosphatidylglycerol (PG) makes up 5–20% of the phospholipids of *Escherichia coli* and is essential for growth in wild-type cells. PG is synthesized from the dephosphorylation of its immediate precursor, phosphatidylglycerol phosphate (PGP) whose synthase in *E. coli* is PgsA. Using genetic, biochemical, and highly sensitive mass spectrometric approaches, we identified an alternative mechanism for PG synthesis in *E. coli* that is PgsA independent. The reaction of synthesis involves the conversion of phosphatidylethanolamine and glycerol into PG and is catalyzed by ClsB, a phospholipase D-type cardiolipin synthase. This enzymatic reaction is demonstrated herein both *in vivo* and *in vitro* as well as by using the purified ClsB protein. When the growth medium was supplemented with glycerol, the expression of *E. coli* ClsB significantly increased PG and cardiolipin levels, with the growth deficiency of *pgsA* null strain also being complemented under such conditions. Identification of this alternative mechanism for PG synthesis not only expands our knowledge of bacterial anionic phospholipid biosynthesis, but also sheds light on the biochemical functions of the *cls* gene redundancy in *E. coli* and other bacteria. Finally, the PGP-independent PG synthesis in *E. coli* may also have important implications for the understanding of PG biosynthesis in eukaryotes that remains incomplete.

In *Escherichia coli*, depending on growth phase and conditions, phosphatidylglycerol (PG)<sup>2</sup> can account for 5–20% of the total phospholipid content, with the remainder mainly comprising phosphatidylethanolamine (PE) and cardiolipin (CL) (1, 2). Besides serving as a basic membrane component (2, 3), PG also plays critical roles in SecA-dependent protein translocation, is involved in the initiation of DNA replication at *oriC*, and is required for the proper location of the division septum at mid-cell (4–7). In *E. coli*, PG is synthesized by a system of enzymes first described by Eugene Kennedy and colleagues (1)

(Fig. 1). In the initial steps of the pathway, the intermediate cytidine diphosphate-diacylglycerol (CDP-DAG) is formed from a condensation reaction between phosphatidic acid (PA) and cytidine triphosphate. The enzyme phosphatidylglycerol phosphate (PGP) synthase (PgsA) then catalyzes a reaction between CDP-DAG and glycerol-3-phosphate to yield PGP, which in turn is dephosphorylated to PG by three PGP phosphatases (PgpA, PgpB, and PgpC) (8). PG is a direct precursor of CL, whose synthesis is mediated by three CL synthase genes in *E. coli* (2).

Deletion of the *pgsA* gene in *E. coli* blocks the synthesis of PG and CL (5, 9, 10). The  $\Delta$ *pgsA* mutant strain is not viable unless it also harbors mutations in the *lpp* and *rscF* genes (10). The *lpp* mutation prevents accumulation of a nascent major outer membrane lipoprotein that requires PG for its modification (5, 9, 11), whereas the *rscF* mutation prevents the lysis of  $\Delta$ *pgsA* cells at the temperature of 37–42 °C (12). Thin-layer chromatography (TLC) and direct injection MS analysis have shown that the  $\Delta$ *pgsA* strain (UE54) lacks detectable PG and CL, but accumulates phosphatidic acid, CDP-diacylglycerol, and *N*-acyl-phosphatidylethanolamine (*N*-acyl-PE) (13).

In this study, using highly sensitive normal phase liquid chromatography/mass spectrometry (LC/MS) (2, 14), we unexpectedly detected small amounts of PG species in  $\Delta$ *pgsA* cells. We found that the formation of PG species in these mutant cells is catalyzed by cardiolipin synthases (Cls), with ClsB playing a dominant role. Furthermore, we purified the ClsB protein and demonstrated its PG synthesis activity using PE and glycerol as substrates. Elucidation of this PGP-independent PG synthesis not only expands our knowledge of anionic phospholipid biosynthesis and metabolism but also sheds light on the biochemical functions of the multiple *cls* genes found in *E. coli* and many other bacteria.

## Results


*LC/MS Reveals pgsA-independent and cls-dependent PG Formation in E. coli*—Under the normal phase LC conditions used in this study, the major *E. coli* glycerophospholipids elute in the following order: PG (~11–12 min), CL (~12–14 min), PE (~16–17 min), and PA (~20–21 min). As identified by the exact mass measurement and MS/MS analysis, wild-type *E. coli* cells contain mainly PG (32:1), PG (33:1), PG (34:2), and PG (34:1), where the numbers of acyl chain carbon atoms and double bonds or double bond equivalents (such as cyclopropane) appear in parentheses (Fig. 2A). Surprisingly, when the total lipid extract of  $\Delta$ *pgsA* (BKT25) cells was subjected to the same

\* This work was supported by the Lipid Maps Collaborative Grant GM069338 and EY023666 from the National Institutes of Health. The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

[5] This article contains supplemental Figs. S1 and S2.

<sup>1</sup> To whom correspondence should be addressed: P.O. Box 3711, Durham, NC 27710. Tel.: 919-684-3005; E-mail: ziqiang.guan@duke.edu.

<sup>2</sup> The abbreviations used are: PG, phosphatidylglycerol; PGP, phosphatidylglycerol phosphate; CDP-DAG, CDP-diacylglycerol; CL, cardiolipin; ClsA, ClsB, or ClsC, CL synthases encoded by the *clsA*, *clsB*, or *clsC* genes, respectively; ESI, electrospray ionization; PA, phosphatidic acid; PE, phosphatidylethanolamine; PLD, phospholipase D.



**FIGURE 1. Biosynthetic pathways and representative structures of *E. coli* glycerophospholipids.** A previously unrecognized mode of PG synthesis involves the conversion of PE into PG by ClsB is the subject of this study. The acyl compositions as drawn in the chemical structures only represent one of the major species.

normal phase LC/MS analysis, PG species were still detectable, albeit at trace levels (<0.1% of the wild-type levels) (Fig. 2B). We confirmed that these PG species were, in fact, synthesized by the  $\Delta pgsA$  strain by performing control experiments that ruled out the possibility that these lipids represented contaminants or were carried over from previous analyses. According to the Kennedy pathway (Fig. 1),  $pgsA$  deletion should completely block PG biosynthesis. This was indeed concluded based on TLC and direct injection MS analysis of  $pgsA$  null mutant (UE54) cells (13). Our detection of trace levels of PG species in the  $\Delta pgsA$  (BKT25) mutant was only possible when the highly sensitive normal phase LC/MS was performed, thus providing an important clue of the existence of other mechanism(s) for PG synthesis. Moreover, it is worth noting that the acyl chain compositions of the residual PG species in the  $\Delta pgsA$  (BKT25) strain (Fig. 2B) differed from those found in wild-type cells (Fig. 2A), implying that the PG species in these two strains might not be formed via the same biosynthetic route.

While profiling the glycerophospholipids of other *E. coli* mutants, we found, unexpectedly, that PG was not detectable when all three paralogous cardiolipin synthase (*cls*) genes (*i.e.* *clsA*, *clsB*, and *clsC*) were deleted from the  $\Delta pgsA$  (BKT25) strain (Fig. 2C). The combined  $pgsA$  and triple *cls* gene deletion mutant ( $\Delta pgsA \Delta clsABC$  (BKT29)) was previously generated in studies that led to our discovery of a third cardiolipin synthase (ClsC) in *E. coli* (2). The  $\Delta pgsA \Delta clsABC$  (BKT29) mutant lacks detectable PG and CL, regardless of growth phase or conditions (Fig. 2C). Intriguingly, PG was still detectable if any one of the

three *cls* genes was not deleted, indicating that each of the *cls* genes might contribute to *in vivo* PG synthesis in the  $\Delta pgsA$  mutant. However, the relative contributions of the three *cls* genes to PG synthesis remain to be delineated (for reasons that the relative PG levels in *E. coli* vary drastically with growth conditions).

To further assess whether Cls proteins are involved in the synthesis of PG *in vivo*, we cloned each of the *cls* genes into the arabinose-inducible pBAD30 expression vector (15) and introduced the plasmids into the  $\Delta pgsA \Delta clsABC$  (BKT29) mutant strain. The transformants were grown to stationary phase ( $A_{600}$  of 1~2) in medium supplemented with carbenicillin and 0.02% arabinose. LC/MS/MS analysis of the total lipids extracted from these cells indicated that PG levels were increased upon ClsB expression but not when ClsA or ClsC were expressed (data not shown). In all cases, neither PG nor CL production was discernible by TLC analysis (Fig. 3A).

**Synthesis of PG by ClsB Requires Glycerol**—All three *E. coli* Cls belong to the phospholipase D (PLD) superfamily, with each containing two HKD motifs (Fig. 4) (2, 16). PLD catalyzes the hydrolysis of phospholipids into PA and the corresponding headgroup (17). It is also known that in the presence of a primary alcohol (*e.g.* butanol), PLD can catalyze a trans-phosphatidyl transfer reaction to yield a phosphatidyl alcohol (17, 18). We speculated that any PG formed by Cls would result from such a trans-phosphatidyl transfer reaction, and thus supplemented the growth medium with glycerol to a final concentration of 0.4% (v/v). As shown by TLC analysis of the total lipids extracted from stationary phase cells (Fig. 3B), ClsB expression in conjunction with glycerol supplementation restored the production of PG and CL in the  $\Delta pgsA \Delta clsABC$  (BKT29) mutant to wild-type levels. The identities of ClsB-produced PG and CL species were further confirmed by normal phase LC/MS/MS analysis of total lipid extracts from cells expressing this protein (Fig. 3, C and D). In contrast, the levels of PG and CL upon expression of ClsA or ClsC remain very low (Fig. 3B). As such, we chose to focus on the role of ClsB in the *cls*-mediated PG formation. The glycerol-dependent PG synthesis by *clsB* was also demonstrated by an *in vitro* assay using *clsB*-expressing BKT29 membranes (supplemental Fig. S1).

**ClsB Synthesizes PG Using PE as a Substrate**—To identify the substrate (or phosphatidyl donor) used for PG synthesis by ClsB, we paid special attention to PE as it was noted that the composition of PG acyl chains (Fig. 3C) very closely matched those of PE (Fig. 3E), suggesting that the phosphatidyl groups of the PG species might be directly transferred from PE species in the  $\Delta pgsA \Delta clsABC$  (BKT29) mutant. To test whether PG could indeed be formed from PE by ClsB,  $^{32}\text{P}$ -labeled PE was prepared from BKT29 *E. coli* cells by supplementing the growth medium with  $^{32}\text{P}$ -labeled  $\text{PO}_4$ . Following fractionation on a DEAE column, the partially purified  $^{32}\text{P}$ -labeled PE substrate was incubated with cell membranes derived from  $\Delta pgsA \Delta clsABC$  (BKT29) cells expressing a vector control (pBAD30), wild-type ClsB, or a ClsB-H113A mutant. As shown by TLC and phosphorimaging analysis (Fig. 5), a significant amount of  $^{32}\text{P}$ -labeled PG was generated by membranes expressing wild-type ClsB, indicating that PE was indeed converted into PG by ClsB. In contrast, no

## Synthesis of PG by an *E. coli* Cardiolipin Synthase




FIGURE 2. PG species are observed in the *E. coli*  $\Delta pgsA$  (BKT25) mutant but is completely absent in the  $\Delta pgsA \Delta clsABC$  (BKT29) mutant. Total lipids extracted from stationary phase cells were analyzed by normal phase LC-ESI/MS/MS in the negative ion mode. A, mass spectrum showing the  $[M-H]^-$  ions of PG species from wild-type *E. coli* cells. B, residual PG ion species are detectable in the  $\Delta pgsA$  (BKT25) mutant. C, PG is not detectable in the  $\Delta pgsA \Delta clsABC$  (BKT29) mutant.




FIGURE 3. Synthesis of PG and CL by ClsB in the  $\Delta pgsA \Delta clsABC$  (BKT29) mutant cells expressing ClsA, ClsB, or ClsC. The trace spot detected near CL in the vector control sample was previously identified by LC/MS/MS to be undecaprenyl-phosphate ( $C_{55}$ -P) (2). B, the addition of glycerol to the growth medium greatly increased the production of PG and CL by ClsB (to near wild-type levels). C and D, MS analysis of PG and CL produced as a result of ClsB expression and glycerol supplementation in BKT29. PG (C) and CL (D) were detected by LC/ESI/MS in the negative ion mode primarily as singly charged  $[M-H]^-$  and doubly charged  $[M-2H]^{2-}$  ions, respectively. The acyl compositions of PG species are almost identical to those of PE (E), hinting the phosphatidyl groups of PG were transferred from PE species.

PG was formed when membranes expressing the vector control or the ClsB-H113A mutant were used (Fig. 5).

To definitively demonstrate that ClsB catalyzes the conversion of PE to PG *in vitro*, we carried out this purification of ClsB

protein. For this, pET vector constructs encoding C terminally FLAG-tagged wild-type ClsB or the protein containing mutations in either of the two HKD motifs (H113A and H291A) were transformed into *E. coli* strain C41 (DE3). The FLAG-tagged

		*	
<i>ClsA</i>	215	FLRRMDLRC	HRKMIMIDNYIAYTGSMNMVDPRYFKQDAGVGQWIDLARMEGPIA 269
<i>ClsB</i>	105	RTN-VFRRM	HRRKI VVIDARI AF I GGLNYSAEHMSSYGP - - EAKQDYAVRLEGP I V 156
<i>ClsC</i>	121	DFSRLNRRM	HNKSF TVDGVVTLVGGRNIGDAYFGAGEE - - PLFSDLDVMA I GPVV 173
			*
<i>ClsA</i>	392	GVK I YQFE - - - - -	GGLLHTKSVLVDGELSLVGTVNLDMRSLW 428
<i>ClsB</i>	278	GVQVFEYR - - - - -	RRPLHGKVALMDHWATVGSSNLDPLSLS 314
<i>ClsC</i>	339	GVELYELKPTREQSSTLHDRG I	TGNSGASLHAKTFSIDGKT VFI GSFNFDPRSTL 393

FIGURE 4. The three *E. coli* cardiolipin synthases (*ClsA*, *ClsB*, and *ClsC*) contain the two HKD motifs (boxed sequences) found in phospholipase D. The conserved His residues (indicated by asterisks) in the HKD motifs were subjected to mutagenesis.




FIGURE 5. *In vitro* conversion of PE to PG by *ClsB*. [ $^{32}$ P]PG was formed by mixing membranes derived from BKT29 cells expressing wild-type *ClsB* and partially purified  $^{32}$ P-labeled PE in the presence of 100 mM glycerol. In contrast, no PG was formed using membranes from cells transformed with an empty vector or expressing the *ClsB*<sup>H113A</sup> mutant. The presence of  $^{32}$ P-labeled lyso-PE likely resulted from partial hydrolysis of PE. The spot at the top of the second lane concurrent with PG formation is likely acyl-PG, a known PG derivative in *E. coli*.

proteins were purified to homogeneity using anti-FLAG M2 affinity gel resin (Fig. 6A). To perform *in vitro* enzyme activity assays, synthetic PE (17:0/14:1) and penta-deuterated glycerol ( $d_5$ -glycerol) were mixed with each of three recombinant *ClsB* proteins (Fig. 6B). After incubation, the reaction solutions were subjected to lipid extraction followed by normal phase LC/MS/MS analysis. As shown in Fig. 6C, the wild-type *ClsB*-FLAG protein produced the expected product,  $d_5$ -PG (whose [M-H]<sup>-</sup> ion is observed at  $m/z$  710.5). In contrast, the two catalytically inactive HKD mutant proteins, *ClsB*<sup>H113A</sup>-FLAG and *ClsB*<sup>H291A</sup>-FLAG, were unable to convert PE into PG (Fig. 6, D and E).

MS/MS analysis further confirmed the  $m/z$  710.5 species produced by *ClsB* (Fig. 6C) as the [M-H]<sup>-</sup> ion of  $d_5$ -PG derived from PE (17:0/14:1) and  $d_5$ -glycerol. As shown in Fig. 6F, the  $m/z$  158.03 product ion is derived from the cyclic phosphodiester of penta-deuterated glycerol; the corresponding  $m/z$  153.0 ion is a signature product ion in the MS/MS spectra of non-

deuterated glycerophospholipids (19). The  $m/z$  225.190 and 269.252 ions correspond to the carboxylic anions of the C17:0 and C14:1 fatty acids, respectively, with both being derived from the synthetic PE (17:0/14:1) substrate. The MS/MS spectrum of the [M-H]<sup>-</sup> ion of PE (17:0/14:1) and its fragmentation scheme are shown in Fig. 6G.


Other phospholipids were tested as potential substrates of *ClsB*, including synthetic standards of CDP-DAG, PA, and PS. None of these was utilized by *ClsB* to synthesize PG.

*ClsB* Uses Two PG Molecules to Synthesize CL—Although the role of *ClsB* as a cardiolipin synthase has been well established (2, 16), characterization of its substrate(s) remains incomplete. Previously, PG was identified as a substrate for *ClsB*, however, this finding was based on an *in vitro* study using membrane preparations (16), and as such could not rule out the possible use of other membrane-derived species as substrate(s). The availability of purified *ClsB* protein allowed us to address this question. Using synthetic PG (17:0/14:1) as substrate, *ClsB*-FLAG produced a single CL species whose molecular weight is consistent with the condensation of two synthetic PG (17:0/14:1) molecules (Fig. 7). This result provides the first experimental evidence that *ClsB* employs the classical “prokaryotic” mechanism to synthesize CL (3).

*ClsB* Complements Deficiencies of a  $\Delta$ *pgsA* Mutant—An *E. coli* *pgsA* null mutant requires mutations in the *lpp* and *rcsF* genes to be viable (9, 10). Given that over-expression of *ClsB* leads to the production of near wild-type levels of PG and CL in the BKT29 mutant ( $\Delta$ *pgsA*  $\Delta$ *clsABC*, derived from UE54) when the growth medium was supplemented with glycerol, we tested whether *ClsB* expression could functionally complement the growth deficiency of a *pgsA*::*Kan*<sup>R</sup> deletion in a wild-type background (*i.e.* without requiring additional suppressor mutations). Accordingly, two pBAD30 constructs containing either *pgsA* or *clsB* were individually transformed into the wild-type *E. coli* strain (W3110), followed by deletion of the *pgsA* gene from the chromosome by P1<sub>vir</sub> transduction, as described previously (2).

As demonstrated by a spot assay (Fig. 8A), the pBAD-*clsB* *pgsA*::*Kan*<sup>R</sup> strain (CL15) required the addition of both arabinose and glycerol for growth. For comparison, the growth of a pBAD-*pgsA* *pgsA*::*Kan*<sup>R</sup> strain (CL14) required neither additional arabinose nor glycerol, suggesting that a minimal level of *pgsA* expression is sufficient to maintain cell viability. In fact, over-expression of *pgsA* seems detrimental to cells, as reflected by the smaller colonies that appeared upon induction with arabinose (Fig. 8A).

## Synthesis of PG by an *E. coli* Cardiolipin Synthase



**FIGURE 6. Purified ClsB protein catalyzes the conversion of PE into PG in the presence of glycerol.** *A*, SDS-PAGE analysis of purified wild-type ClsB-FLAG, ClsB<sup>H113A</sup>-FLAG, and ClsB<sup>H291A</sup>-FLAG proteins. *B*, proposed reaction scheme of the conversion of synthetic substrate PE (17:0/14:1) to product *d*<sub>5</sub>-PG (17:0/14:1) by ClsB in the presence of *d*<sub>5</sub>-glycerol. *C–E*, the expected *d*<sub>5</sub>-PG (17:0/14:1) ([M-H]<sup>−</sup> ion at *m/z* 710.5) is produced by wild-type ClsB-FLAG protein, but not by ClsB<sup>H113A</sup>-FLAG or ClsB<sup>H291A</sup>-FLAG mutant protein. *F*, MS/MS spectrum of *d*<sub>5</sub>-PG (17:0/14:1) ([M-H]<sup>−</sup> ion at *m/z* 710.5) and the fragmentation scheme for the major product ions. *G*, MS/MS spectrum of substrate PE (17:0/14:1) ([M-H]<sup>−</sup> ion at *m/z* 674.5) and the fragmentation scheme for the major product ions.

Total lipid analysis by TLC shows that expression of ClsB produced significant levels of PG and CL in the *pgsA::Kan<sup>R</sup>* strain (CL15), comparable with those in the wild-type or the *pgsA*-covered  $\Delta$ *pgsA* strains (Fig. 8*B*). These results demonstrated that with glycerol supplementation, ClsB expression could sufficiently complement the deficiencies of the  $\Delta$ *pgsA* mutant in cell growth (without additional suppressor mutations), as well as in PG and CL synthesis.

### Discussion

Pathways for the biosynthesis of the major *E. coli* glycerophospholipids (including PE, PG, and CL) were first described by Hirschberg and Kennedy (3) over 40 years ago. The key technique employed for their investigations was radioisotopic labeling (3), primarily involving the use of <sup>32</sup>P-labeled phosphate and <sup>14</sup>C-labeled glycerol or fatty acids as tracing substances. Radiolabeling techniques also played critical roles in the discovery and characterization of the biosynthetic enzymes of these glycerophospholipids (1). Although the power of radiolabeling techniques is unquestionable, such approaches are limited in terms of molecular specificity and in detecting minor species in a complex mixture.

The past decade has seen a dramatic increase in the application of MS to lipid research (4, 20–22). Lipid MS, like all other biological applications of MS, was revolutionized by the introduction of soft ionization techniques, most notably electrospray ionization (ESI) (23) and matrix-assisted laser desorption ionization (MALDI) (24). Furthermore, the combination of on-line chromatographic separation with ESI/MS detection has greatly improved the applicability of MS to the analysis of complex mixtures. In particular, LC/MS has greatly improved the

detection of a minor species by separating them from major species, thus reducing or eliminating ion signal suppressions from the latter. Signal suppression is a common issue in direct injection MS, which is often responsible for the failure to detect the minor species in a mixture. As demonstrated in this study, normal phase LC/MS is particularly well suited for the detection and characterization of glycerophospholipids as these lipid species can be separated based on their headgroups (or charges). Our detection of residual PG species in *E. coli*  $\Delta$ *pgsA* mutant cells benefited from the application of normal phase LC/MS. Indeed, the exceptional sensitivity and specificity afforded by modern high-resolution LC/MS/MS instruments have facilitated the discovery and characterization of numerous minor, novel lipid species (25–27), as well as functional elucidation of novel genes involved in lipid biosynthesis and metabolism (8, 28, 29), including the recent discovery of the first mammalian PGP phosphatase (29). In this study, the LC/MS-based approach was critical in revealing the PE to PG conversion previously unknown in *E. coli*, extending the studies on the inter-conversion of phospholipids observed in other bacteria (30–32). For example, Lombardi and Fulco (31) reported that PE could be directly made from PG in *Bacillus megaterium*. Walton and Goldfine (32) reported *in vitro* trans-phosphatidyl transfer activities that allowed remodeling of the headgroups of *Clostridium butyricum* membrane phospholipids, including the formation of PE from PG without the formation of PS intermediates. These observations were, however, all based exclusively on radioisotope-labeling techniques and lacked genetic and detailed biochemical characterization.




FIGURE 7. **Purified ClsB-FLAG protein uses two PG molecules to synthesize CL (the classical prokaryotic mode).** After incubating purified ClsB-FLAG protein with synthetic PG (17:0/14:1) in a reaction buffer, the solution was subjected to lipid extraction and analysis by normal phase-LC/MS/MS. **A**, a single molecular species of CL was produced, and is detected as the  $[M-2H]^{2-}$  ion at  $m/z$  659.449. This corresponds to a molecular weight of 1320.914, consistent with CL formed from the condensation of two synthetic PG (17:0/14:1) molecules. **B**, MS/MS analysis further supports that the CL product was synthesized from the condensation of two synthetic PG (17:0/14:1) molecules (**C**). The fragmentation scheme of major product ions observed in the MS/MS spectrum is illustrated (**C**).

The physiological significance of the alternative mechanism of PG synthesis mediated by a CL synthase reported here is unknown. The ability to remodel pre-existing phospholipids may allow bacteria to adapt to changing environmental conditions without resorting to *de novo* phospholipid synthesis (32). The recent revelation that multiple paralogous *cls* genes exist in *E. coli* and many other bacteria calls for the study of their biochemical and physiological functions (1, 2, 33, 34). Given the dual functions of ClsB in *E. coli* phospholipid synthesis as described above, it is possible that some bacterial *cls* genes may be involved in inter-converting zwitterionic lipids (e.g. PE) to anionic phospholipids (e.g. PG) under certain environmental stress conditions.

Finally, the identification of an PGP-independent PG synthesis in *E. coli* may have important implications for fully understanding PG synthesis in eukaryotes (35). For example, the first yeast PGPase (*Gep4*) and mammalian PGPase (*PTPMT1*) were identified only during the last few years (29, 36). However, as reported in both studies, considerable amounts of PG species were still present in the *PGPase*-null yeast ( $\Delta$ *Gep4*) (36) and mammalian cell ( $\Delta$ *PTPMT1*) mutants (29), indicating the existence of additional PGPase(s) or alternative mechanism(s) for PG synthesis in these eukaryotic cells. It is particularly intriguing that the acyl chain compositions of the PG species in

*ptpmt1-KO* mouse embryonic fibroblasts differed from those of the accumulated PGP species, strongly implying that not all PG species were derived from PGP in such cells (29). Given that no PTPMT1 homologous genes have been identified in the mouse genome, it is tempting to speculate that some of these residual PG species in the *ptpmt1-KO* mouse embryonic fibroblast cells might be formed via a PLD-like trans-phosphatidyl transfer activity. In a preliminary study, we demonstrated the conversion of PE into PG in yeast by overexpressing *clsB* in the  $\Delta$ *Gep4* mutant cells (supplemental Fig. S2).

### Experimental Procedures

**Materials**—Silica Gel 60 TLC plates, L-(+)-arabinose, and glycerol were obtained from EMD Chemicals (Gibbstown, NJ). Agar, tryptone, and yeast extract were purchased from Difco. Sodium chloride and HEPES were from VWR International (West Chester, PA). Tween 20 and the bicinchoninic acid protein concentration determination kit were from Thermo Fisher Scientific (Waltham, MA). DEAE-cellulose (type DE52) was from Whatman (Florham Park, NJ). Isopropyl 1-thio- $\beta$ -D-galactopyranoside was from Invitrogen. Reagent grade chloroform, methanol, hydrochloric acid, sulfuric acid, ethanol, and *d*<sub>5</sub>-glycerol were from Sigma. Synthetic PG, PA, PE, and CDP-DAG were from Avanti Polar Lipids (Alabaster, AL). [<sup>32</sup>P]PO<sub>4</sub>

## Synthesis of PG by an *E. coli* Cardiolipin Synthase




FIGURE 8. **Expression of ClsB complements the defects of a  $\Delta pgsA::Kan^R$  mutant in cell growth and in PG and CL synthesis.** *A*, a spot assay was conducted with a 10-fold series dilution of *E. coli*  $\Delta pgsA::Kan^R$  strains covered by plasmids expressing either *pgsA* or *clsB*. The strains were grown on LB plates in the presence or absence of 0.4% glycerol and/or 0.02% arabinose. The growth of the *pBAD-clsB*  $\Delta pgsA::Kan^R$  strain required both arabinose induction and glycerol supplementation. In contrast, the *pBAD-pgsA*  $\Delta pgsA::Kan^R$  strain required neither. *B*, TLC analysis of lipid extracts from wild-type, and *pBAD-pgsA* and *pBAD-clsB*  $\Delta pgsA::Kan^R$  *E. coli* strains.

was from PerkinElmer Life & Analytical Sciences (Waltham, MA).

**Bacterial Strains and Growth Conditions**—All *E. coli* strains used in this study are listed in Table 1. The *E. coli* MG1655 and W3110 strains are designated as the wild-type strains with respect to their glycerophospholipid composition. Liquid LB medium (10 g/liter of tryptone, 5 g/liter of yeast extract, and 10 g/liter of NaCl) was used to culture *E. coli*. Solid medium consisted of LB medium with the addition of 15 g/liter of agar. For strain selection purposes, cell cultures were supplemented with kanamycin (50 mg/liter) or carbenicillin (100 mg/liter). All strains were grown at 30 or 37 °C as noted, and cell density was measured as absorption at 600 nm ( $A_{600}$ ) using a DU spectrophotometer (Beckman Coulter, Brea, CA).

**Construction of Chromosomal Mutants Lacking *cls* Genes**—Chromosomal deletions of *cls* genes were constructed using the Keio Collection (the *E. coli* K12 single-gene deletion library), which served as the mutation donor (37). A gene of interest was replaced by a kanamycin cassette with flanking FLP sequences in each Keio mutant.  $P_{1, vir}$  transduction and subsequent kanamycin incision were performed according to a previous description (2). All strains with *cls* deletions were further verified by PCR.

**DNA Manipulations and Plasmid Constructions**—All plasmids used in this study are listed in Table 2. Plasmids were isolated using the Qiagen Spin Miniprep kit, and DNA fragments were isolated with the Qiaquick Spin Kits (Qiagen, Valencia, CA). Phusion High Fidelity DNA polymerase (New England Biolabs, Ipswich, MA),  $T_4$  DNA ligase (Invitrogen), and restriction endonucleases (New England Biolabs) were used according to the manufacturer's instructions. Expression of *clsB* from the low-copy pBAD30 plasmid was carried out as described previously, using pBAD-B (2). Site-directed mutagenesis was used to mutate His residues in each HKD motif of ClsB to Ala (Fig. 1). For protein expression and purification purposes, the *clsB* gene and DNA encoding the corresponding His-Ala mutants were also cloned into pET vectors. DNA encoding a C-terminal FLAG epitope was fused to each gene, which were cloned into the XbaI and HindIII sites of vector pET21b. The resulting FLAG-tagged ClsB constructs were designated as pET21b-B, pET21b-B-H113A, and pET21b-B-H291A, respectively. To generate the pBAD-*pgsA* vector, the *pgsA* gene from W3110 cells was amplified and cloned into the XbaI and HindIII sites of plasmid pBAD30. All constructs were verified by DNA sequencing at the Duke DNA Sequencing Facility.

**TABLE 1**  
*E. coli* strains used in this study

Strain	Genotype	Source or Ref.
W3110	Wild-type	2
MG1655	Wild-type	2
JW1241	BW25113 $\Delta$ clsA::Kan <sup>R</sup>	1
JW0772	BW25113 $\Delta$ clsB::Kan <sup>R</sup>	1
JW5150	BW25113 $\Delta$ clsC::Kan <sup>R</sup>	1
UE54	MG1655 <i>lpp2</i> $\Delta$ ara714 <i>rcsF::miniTn10cam</i> $\Delta$ pgsA::FRT-Kan-FRT	2
BKT25	MG1655 <i>lpp2</i> $\Delta$ ara714 <i>rcsF::miniTn10cam</i> $\Delta$ pgsA	2
BKT29	BKT25 $\Delta$ clsA, $\Delta$ clsB, $\Delta$ clsC, $\Delta$ ymdB::Kan <sup>R</sup>	2
BKT30	BKT25 $\Delta$ clsB::Kan <sup>R</sup>	2
CL01	BKT25 $\Delta$ clsA::Kan <sup>R</sup>	This work
CL02	BKT25 $\Delta$ clsA (derived from CL01)	This work
CL03	BKT25 $\Delta$ clsA, $\Delta$ clsB::Kan <sup>R</sup>	This work
CL04	BKT25 $\Delta$ clsA, $\Delta$ clsB (derived from CL03)	This work
CL06	BKT25 $\Delta$ clsA, $\Delta$ clsC::Kan <sup>R</sup>	This work
CL07	BKT25 $\Delta$ clsA, $\Delta$ clsC (derived from CL06)	This work
CL08	BKT25 $\Delta$ clsB (derived from BKT30)	This work
CL09	BKT25 $\Delta$ clsB, $\Delta$ clsC::Kan <sup>R</sup>	This work
CL10	BKT25 $\Delta$ clsB, $\Delta$ clsC (derived from CL09)	This work
CL11	BKT25 $\Delta$ clsC::Kan <sup>R</sup>	This work
CL12	BKT25 $\Delta$ clsC (derived from CL11)	This work
CL14	W3110 pBAD30-pgsA, $\Delta$ pgsA::Kan <sup>R</sup>	This work
CL15	W3110 pBAD30-B, $\Delta$ pgsA::Kan <sup>R</sup>	This work

**TABLE 2**  
*E. coli* plasmids used in this study

Plasmid	Genotype	Source or Ref.
pCP20	FLP recombinase expression; Amp <sup>R</sup> Cam <sup>R</sup> ; temperature-sensitive replicon	2
pBAD30	Low copy number expression plasmid	2
pBAD-A	Expression of clsA on pBAD30	2
pBAD-B	Expression of clsB on pBAD30	2
pBAD-B-H113A	Expression of clsB with H113A substitution on pBAD30	2
pBAD-B-H291A	Expression of clsB with H291A substitution on pBAD30	2
pBAD-C	Expression of clsC on pBAD30	2
pBAD-pgsA	Expression of pgsA on pBAD30	This work
pET21b	Expression plasmid	Novagen
pET21b-B	Expression of clsB-FLAG on pET21b	This work
pET21b-B-H113A	Expression of clsB-FLAG with H113A substitution on pET21b	This work
pET21b-B-H291A	Expression of clsB-FLAG with H291A substitution on pET21b	This work

**Lipid Extraction and TLC Analysis**—Lipid extraction was performed using a neutral Bligh-Dyer method (38). Cell pellets were washed twice with phosphate-buffered saline (PBS) before extraction. The washed pellets were then suspended in 1.9 ml of PBS, followed by the addition of 4.8 ml of methanol and 2.4 ml of chloroform to create a single-phase solution. The solution was incubated for 30 min at room temperature with intermittent mixing. After centrifugation at  $3500 \times g$  for 10 min, the supernatant was converted into a two-phase solution by adding 2.4 ml of PBS and 2.4 ml of chloroform. After centrifugation at  $3500 \times g$  for 10 min, the lower phase was recovered and dried under a stream of nitrogen gas. For TLC analysis, the dried lipid extracts were each dissolved in a 100  $\mu$ l of chloroform/methanol (2:1, v/v). Approximately 1–5  $\mu$ l of the solution was spotted onto a TLC plate. The TLC plate was developed in tanks equilibrated with chloroform/methanol/acetic acid (65:25:10, v/v). After drying the plate, lipids were visualized by spraying 10% sulfuric acid in ethanol (v/v), followed by charring on a hot plate (2).

**Isolation of [<sup>32</sup>P]PE**—To prepare radiolabeled [<sup>32</sup>P]PE, a 3-ml culture of *E. coli* BKT29 was grown overnight. Cells were harvested and washed three times by distilled water. The cells were diluted 100-fold with 10 ml of G56 medium (39) containing 100  $\mu$ Ci of [<sup>32</sup>P]orthophosphate and the cells were grown at 30 °C for 5 h. Lipid extraction and purification of PE using a DE52-cellulose column was carried out as previously described (40).

To identify the PE-containing fractions, 10  $\mu$ l of each fraction was loaded onto a silica TLC plate, which was developed using a solvent mixture consisting chloroform/methanol/acetic acid (65:25:10, v/v). After drying under hot air, the TLC plate was analyzed with a PhosphorImager system (Molecular Dynamics, Sunnyvale, CA). Fractions that contain [<sup>32</sup>P]PE were subjected to lipid extraction using a Bligh-Dyer method (38) as described above.

**Liquid Chromatography Mass Spectrometry of Lipids**—Normal phase LC was performed on an Agilent 1200 Quaternary LC system equipped with an Ascentis Silica HPLC column (5  $\mu$ m, 25 cm  $\times$  2.1 mm) from Sigma. Mobile phase A consisted of chloroform/methanol/aqueous ammonium hydroxide (800:195:5, v/v); mobile phase B consisted of chloroform/methanol/water/aqueous ammonium hydroxide (600:340:50:5, v/v); mobile phase C consisted of chloroform/methanol/water/aqueous ammonium hydroxide (450:450:95:5, v/v). The elution program consisted of the following: 100% mobile phase A was held isocratically for 2 min and then linearly increased to 100% mobile phase B over 14 min and held at 100% B for 11 min. The LC gradient was then changed to 100% mobile phase C over 3 min and held at 100% C for 3 min, and finally returned to 100% A over 0.5 min and held at 100% A for 5 min. With a total flow rate of 300  $\mu$ l/min, the LC eluent was injected into the ion spray source of a TripleTOF® 5600 quadrupole time-of-flight tandem mass spectrometer (AB SCIEX, Framingham, MA). Instrumen-

## Synthesis of PG by an *E. coli* Cardiolipin Synthase

tal settings for negative ion ESI and MS/MS analysis of lipid species were as follows: electrospray ionization voltage (IS) =  $-4500$  V; current gas (CUR) = 20 psi (pressure); gas-1 (GS1) = 20 p.s.i.; de-clustering potential (DP) =  $-55$  V; and focusing potential (FP) =  $-150$  V. The MS/MS analysis used nitrogen as the collision gas. Data analysis was performed using Analyst TF1.5 software from AB SCIEX.

**Complementation of the  $\Delta$ pgsA::kan<sup>R</sup> Mutant**—Plasmids pBAD-B and pBAD-pgsA were individually transformed into wild-type *E. coli* W3110 cells. The P1 phage was prepared from UE54, a strain containing a chromosomal  $\Delta$ pgsA::FRT-kan<sup>R</sup>-FRT cassette (Table 2). P1<sub>vir</sub> transductions of the W3110 strain containing either plasmid pBAD-B or pBAD-pgsA were performed as described above. After transduction, the recipient cells were incubated at 30 °C on LB agar plates containing 50 mg/liter of kanamycin, 100 mg/liter of carbenicillin, 5 mM sodium citrate, arabinose (0, 0.002, 0.02, or 0.2%), and glycerol (0 or 0.4%). The surviving colonies were purified twice with the same growth condition and the chromosomal  $\Delta$ pgsA::kan<sup>R</sup> cassette in each colony was verified by PCR. The  $\Delta$ pgsA::kan<sup>R</sup> strains in the W3110 background complemented by plasmid pBAD-pgsA or pBAD-B were designated as CL14 and CL15, respectively.

To assess the cell viability of the CL14 and CL15 strains, different growth conditions were employed. The CL14 strain was grown in LB medium containing 100 mg/liter of carbenicillin, whereas the CL15 strain was grown in LB medium containing 100 mg/liter of carbenicillin, 0.2% arabinose, and 0.4% glycerol. For each strain, 100  $\mu$ l of cell culture was harvested at an  $A_{600}$  of 1.0, washed twice with 1 ml of LB medium, and re-suspended in 100  $\mu$ l of LB medium. A series of 10-fold dilutions were generated for each strain and 3  $\mu$ l of each diluted solution were spotted onto LB agar plates containing 100 mg/liter of carbenicillin, arabinose (0 and 0.02%), and glycerol (0 and 0.4%). Cells were grown at 30 °C overnight.

**Expression and Purification of ClsB Proteins**—For ClsB protein expression, the pET21b constructs were transformed into strain C41 (DE3) cells. 3-ml cultures were grown overnight at 37 °C and diluted 100-fold into 100 ml of LB medium containing 100 mg/liter of carbencillin. When the cells had grown to  $A_{600}$  of  $\sim 0.5$ , expression of the FLAG-tagged ClsB protein was induced by adding isopropyl  $\beta$ -D-thiogalactoside to a final concentration of 1 mM. The cultures were grown at 17 °C for an additional 6 h with shaking. For ClsB purification, the following procedures were conducted at 4 °C, unless otherwise noted. Cell pellets were washed twice with ice-cold PBS and suspended in 3 ml of lysis buffer containing 20 mM HEPES (pH 8.0) and 150 mM NaCl. The cells were lysed using a French press twice at 16,000 p.s.i., and spun at 10,000  $\times g$  for 30 min to remove cell debris. The supernatant was centrifuged at 200,000  $\times g$  for 1 h to collect membranes, which were homogenized and suspended in a buffer containing 20 mM HEPES (pH 8.0), 150 mM NaCl, 10% glycerol, and 0.5% Tween 20. The protein concentration from the resulting suspension was maintained at 1 mg/ml. To solubilize the membranes, the suspension was incubated with gentle rotation overnight, followed by another centrifugation at 200,000  $\times g$  for 1 h to remove insoluble materials. The resulting soluble fraction was loaded onto a

0.5-ml column of anti-FLAG M2 affinity gel (Sigma) and incubated at 4 °C with gentle rotation for 2 h. The column was washed twice by 10 ml of high salt buffer containing 20 mM HEPES (pH 8.0), 500 mM NaCl, and 0.008% Tween 20. ClsB-FLAG protein was eluted four times using 0.5 ml of elution buffer containing 20 mM HEPES (pH 8.0), 150 mM NaCl, 0.008% Tween 20, and 150 mg/liter of 3 $\times$  FLAG peptide (Sigma). The eluted protein was dialyzed against low salt buffer (20 mM HEPES (pH 8.0), 150 mM NaCl, and 0.008% Tween 20). The purification of ClsB was assessed by SDS-PAGE analysis. Purified ClsB was stored at  $-80$  °C until enzyme assay.

**Enzyme Assay of ClsB**—To analyze membrane PLD activity *in vitro*, crude membranes were prepared from BKT29 cells expressing the pBAD30 control vector, the pBAD-B vector, or the pBAD-B-H113A vector. Membranes were prepared as described previously (2). To perform the *in vitro* assay, 20- $\mu$ l reaction mixtures consisting of PBS (pH 7.4), 10  $\mu$ M  $\beta$ -mercaptoethanol, 2 mM MgCl<sub>2</sub>, 100 mM glycerol (Sigma), 0.008% Tween 20, 1,000 cpm/ $\mu$ l of [<sup>32</sup>P]PE, and 1 mg/ml of cell membranes were incubated at 30 °C for 30 min. After incubation, a 3- $\mu$ l aliquot of each reaction was spotted onto a TLC plate, which was developed in a solvent mixture consisting chloroform/methanol/acetic acid (65:25:10, v/v). The TLC plate was visualized using a PhosphorImager (Molecular Dynamics). To assess the PG synthesis activity of purified ClsB, the reaction solutions consisted of PBS (pH 7.4), 10  $\mu$ M  $\beta$ -mercaptoethanol, 2 mM MgCl<sub>2</sub>, 100 mM *d*<sub>5</sub>-glycerol (Sigma), 0.008% Tween 20, 5  $\mu$ M synthetic PE (17:0/14:1) (Avanti Polar Lipids), and 20 ng/ml of purified proteins. After incubation at 30 °C for 30 min, 88  $\mu$ l of PBS, 120  $\mu$ l of chloroform, and 120  $\mu$ l of methanol were added to generate a two-phase Bligh-Dyer solution. The mixture was vortexed for 2 min and spun at 10,000  $\times g$  for 1 min. 10  $\mu$ l of the lower phase was analyzed by normal phase LC/MS/MS. For assaying *in vitro* enzymatic activity of purified ClsB, a reaction mixture containing 320 mM potassium phosphate (pH 7.0), 10 mM L-mercaptoethanol, 0.008% Tween 20, 5  $\mu$ M synthetic PG (17:0/14:1), and 20 ng/ml of protein was prepared. The reaction mixture was incubated at 30 °C for 30 min, followed by lipid extraction and analysis by normal phase LC/MS/MS, as described above.

**Yeast**—Wild-type BY4743 and gep4 KO yeast strains were ordered from ATCC. For protein expression in yeast, the *E. coli* ClsB gene was fused with N terminus su9<sup>1-69</sup> (36) by PCR and cloned onto p415GPD vector as described previously (29).


**Author Contributions**—C. L., B. K., and Z. G. designed and performed all experiments. J. Z. provide technical advice. C. L. and Z. G. wrote the manuscript.

**Acknowledgments**—We thank Drs. Edward Dennis, H. Alex Brown, Mikhail Bogdanov, and William Dowhan for advice and discussion, and Dr. Jerry Eichler for critically reading the manuscript.

## References


1. Dowhan, W. (2013) A retrospective: use of *Escherichia coli* as a vehicle to study phospholipid synthesis and function. *Biochim. Biophys. Acta* **1831**, 471–494
2. Tan, B. K., Bogdanov, M., Zhao, J., Dowhan, W., Raetz, C. R., and Guan, Z. (2012) Discovery of a cardiolipin synthase utilizing phosphatidylethanol-

- amine and phosphatidylglycerol as substrates. *Proc. Natl. Acad. Sci. U.S.A.* **109**, 16504–16509
3. Hirschberg, C. B., and Kennedy, E. P. (1972) Mechanism of the enzymatic synthesis of cardiolipin in *Escherichia coli*. *Proc. Natl. Acad. Sci. U.S.A.* **69**, 648–651
  4. Dowhan, W. (2009) Molecular genetic approaches to defining lipid function. *J. Lipid Res.* **50**, S305–310
  5. Matsumoto, K. (2001) Dispensable nature of phosphatidylglycerol in *Escherichia coli*: dual roles of anionic phospholipids. *Mol. Microbiol.* **39**, 1427–1433
  6. Mileykovskaya, E., and Dowhan, W. (2005) Role of membrane lipids in bacterial division-site selection. *Curr. Opin. Microbiol.* **8**, 135–142
  7. Xia, W., and Dowhan, W. (1995) *In vivo* evidence for the involvement of anionic phospholipids in initiation of DNA replication in *Escherichia coli*. *Proc. Natl. Acad. Sci. U.S.A.* **92**, 783–787
  8. Lu, Y. H., Guan, Z., Zhao, J., and Raetz, C. R. (2011) Three phosphatidylglycerol-phosphate phosphatases in the inner membrane of *Escherichia coli*. *J. Biol. Chem.* **286**, 5506–5518
  9. Kikuchi, S., Shibuya, I., and Matsumoto, K. (2000) Viability of an *Escherichia coli* pgsA null mutant lacking detectable phosphatidylglycerol and cardiolipin. *J. Bacteriol.* **182**, 371–376
  10. Shiba, Y., Yokoyama, Y., Aono, Y., Kiuchi, T., Kusaka, J., Matsumoto, K., and Hara, H. (2004) Activation of the Rcs signal transduction system is responsible for the thermosensitive growth defect of an *Escherichia coli* mutant lacking phosphatidylglycerol and cardiolipin. *J. Bacteriol.* **186**, 6526–6535
  11. Suzuki, M., Hara, H., and Matsumoto, K. (2002) Envelope disorder of *Escherichia coli* cells lacking phosphatidylglycerol. *J. Bacteriol.* **184**, 5418–5425
  12. Nagahama, H., Sakamoto, Y., Matsumoto, K., and Hara, H. (2006) RcsA-dependent and -independent growth defects caused by the activated Rcs phosphorelay system in the *Escherichia coli* pgsA null mutant. *J. Gen. Appl. Microbiol.* **52**, 91–98
  13. Mileykovskaya, E., Ryan, A. C., Mo, X., Lin, C. C., Khalaf, K. I., Dowhan, W., and Garrett, T. A. (2009) Phosphatidic acid and *N*-acylphosphatidylethanolamine form membrane domains in *Escherichia coli* mutant lacking cardiolipin and phosphatidylglycerol. *J. Biol. Chem.* **284**, 2990–3000
  14. Guan, Z., and Eichler, J. (2011) Liquid chromatography/tandem mass spectrometry of dolichols and polyprenols, lipid sugar carriers across evolution. *Biochim. Biophys. Acta* **1811**, 800–806
  15. Guzman, L. M., Belin, D., Carson, M. J., and Beckwith, J. (1995) Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. *J. Bacteriol.* **177**, 4121–4130
  16. Guo, D., and Tropp, B. E. (2000) A second *Escherichia coli* protein with CL synthase activity. *Biochim. Biophys. Acta* **1483**, 263–274
  17. Selvy, P. E., Lavieri, R. R., Lindsley, C. W., and Brown, H. A. (2011) Phospholipase D: enzymology, functionality, and chemical modulation. *Chem. Rev.* **111**, 6064–6119
  18. Brown, H. A., Henage, L. G., Preininger, A. M., Xiang, Y., and Exton, J. H. (2007) Biochemical analysis of phospholipase D. *Methods Enzymol.* **434**, 49–87
  19. Pulfer, M., and Murphy, R. C. (2003) Electrospray mass spectrometry of phospholipids. *Mass Spectrom. Rev.* **22**, 332–364
  20. Han, X., and Gross, R. W. (2003) Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: a bridge to lipidomics. *J. Lipid Res.* **44**, 1071–1079
  21. Murphy, R. C., Fiedler, J., and Hevko, J. (2001) Analysis of nonvolatile lipids by mass spectrometry. *Chem. Rev.* **101**, 479–526
  22. Quehenberger, O., Armando, A. M., Brown, A. H., Milne, S. B., Myers, D. S., Merrill, A. H., Bandyopadhyay, S., Jones, K. N., Kelly, S., Shaner, R. L., Sullards, C. M., Wang, E., Murphy, R. C., Barkley, R. M., Leiker, T. J., et al. (2010) Lipidomics reveals a remarkable diversity of lipids in human plasma. *J. Lipid Res.* **51**, 3299–3305
  23. Fenn, J. B., Mann, M., Meng, C. K., Wong, S. F., and Whitehouse, C. M. (1989) Electrospray ionization for mass spectrometry of large biomolecules. *Science* **246**, 64–71
  24. Karas, M., and Hillenkamp, F. (1988) Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. *Anal. Chem.* **60**, 2299–2301
  25. Guan, Z., Breazeale, S. D., and Raetz, C. R. (2005) Extraction and identification by mass spectrometry of undecaprenyl diphosphate-MurNAc-pentapeptide-GlcNAc from *Escherichia coli*. *Anal. Biochem.* **345**, 336–339
  26. Guan, Z., Li, S., Smith, D. C., Shaw, W. A., and Raetz, C. R. (2007) Identification of *N*-acylphosphatidylserine molecules in eukaryotic cells. *Biochemistry* **46**, 14500–14513
  27. Ward, W. C., Guan, Z., Zucca, F. A., Fariello, R. G., Kordestani, R., Zecca, L., Raetz, C. R., and Simon, J. D. (2007) Identification and quantification of dolichol and dolichoic acid in neuromelanin from substantia nigra of the human brain. *J. Lipid Res.* **48**, 1457–1462
  28. Cantagrel, V., Lefeber, D. J., Ng, B. G., Guan, Z., Silhavy, J. L., Bielas, S. L., Lehle, L., Hombauer, H., Adamowicz, M., Swiezewska, E., De Brouwer, A. P., Blümel, P., Sykut-Cegielska, J., Houliston, S., Swistun, D., et al. (2010) SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder. *Cell* **142**, 203–217
  29. Zhang, J., Guan, Z., Murphy, A. N., Wiley, S. E., Perkins, G. A., Worby, C. A., Engel, J. L., Heacock, P., Nguyen, O. K., Wang, J. H., Raetz, C. R., Dowhan, W., and Dixon, J. E. (2011) Mitochondrial phosphatase PTPMT1 is essential for cardiolipin biosynthesis. *Cell Metab.* **13**, 690–700
  30. Lombardi, F. J., Chen, S. L., and Fulco, A. J. (1980) A rapidly metabolizing pool of phosphatidylglycerol as a precursor of phosphatidylethanolamine and diglyceride in *Bacillus megaterium*. *J. Bacteriol.* **141**, 626–634
  31. Lombardi, F. J., and Fulco, A. J. (1980) Two distinct pools of membrane phosphatidylglycerol in *Bacillus megaterium*. *J. Bacteriol.* **141**, 618–625
  32. Walton, P. A., and Goldfine, H. (1987) Transphosphatidylase activity in *Clostridium butyricum*: evidence for a secondary pathway by which membrane phospholipids may be synthesized and modified. *J. Biol. Chem.* **262**, 10355–10361
  33. Kawai, F., Shoda, M., Harashima, R., Sadaie, Y., Hara, H., and Matsumoto, K. (2004) Cardiolipin domains in *Bacillus subtilis* Marburg membranes. *J. Bacteriol.* **186**, 1475–1483
  34. Koprivnjak, T., Zhang, D., Ernst, C. M., Peschel, A., Nauseef, W. M., and Weiss, J. P. (2011) Characterization of *Staphylococcus aureus* cardiolipin synthases 1 and 2 and their contribution to accumulation of cardiolipin in stationary phase and within phagocytes. *J. Bacteriol.* **193**, 4134–4142
  35. Henry, S. A., Kohlwein, S. D., and Carman, G. M. (2012) Metabolism and regulation of glycerolipids in the yeast *Saccharomyces cerevisiae*. *Genetics* **190**, 317–349
  36. Osman, C., Haag, M., Wieland, F. T., Brügger, B., and Langer, T. (2010) A mitochondrial phosphatase required for cardiolipin biosynthesis: the PGP phosphatase Gep4. *EMBO J.* **29**, 1976–1987
  37. Baba, T., Ara, T., Hasegawa, M., Takai, Y., Okumura, Y., Baba, M., Datsenko, K. A., Tomita, M., Wanner, B. L., and Mori, H. (2006) Construction of *Escherichia coli* K-12 in-frame, single-gene knockout mutants: the Keio collection. *Mol. Syst. Biol.* **2**, 2006.0008
  38. Blish, E. G., and Dyer, W. J. (1959) A rapid method of total lipid extraction and purification. *Can. J. Biochem. Physiol.* **37**, 911–917
  39. Galloway, S. M., and Raetz, C. R. (1990) A mutant of *Escherichia coli* defective in the first step of endotoxin biosynthesis. *J. Biol. Chem.* **265**, 6394–6402
  40. Kanipes, M. I., Lin, S., Cotter, R. J., and Raetz, C. R. (2001) Ca<sup>2+</sup>-induced phosphoethanolamine transfer to the outer 3-deoxy-D-manno-octulosonic acid moiety of *Escherichia coli* lipopolysaccharide: a novel membrane enzyme dependent upon phosphatidylethanolamine. *J. Biol. Chem.* **276**, 1156–1163




**FIGURE 1S. LC/MS analysis of *in vitro* synthesis of PG using glycerol as a substrate.** ClsB-expressing BKT29 membranes were incubated with *d*<sub>5</sub>-glycerol at various concentrations: A) 1 mM *d*<sub>5</sub>-glycerol; B) 10 mM *d*<sub>5</sub>-glycerol; C) 100 mM *d*<sub>5</sub>-glycerol. The level of PG increases (almost linearly) with the *d*<sub>5</sub>-glycerol concentration. In comparison, PA remains about the same while PE is slightly decreased. Note: due to the differences in ionization efficiency, the ion intensities of PG, PE and PA cannot be used to estimate their relative quantities.

### A) Yeast *Gep4-KO*



### B) Yeast *Gep4-KO + clsB*



**FIGURE 2S. Expression of *ClsB* converts PE into PG in yeast cells.** A) The molecular species of PE and PG in the *Gep4* knockout mutant and wild-type (data not shown) yeast cells have different acyl chain compositions. For example, the most abundant PE species, PE (16:1/18:1) at  $m/z$  714.459, has two mono-unsaturated acyl chains, while the most abundant PG, PG (16:0/18:1) at  $m/z$  747.464, contains only one mono-unsaturated acyl chain. The acyl compositions of PE and PG in wild-type yeast cells are very similar to those in the *Gep4* knockout mutant. B) Expression of *ClsB* in the *Gep4* knockout mutant produces new PG molecular species (with red labels) with the same acyl compositions as the most abundant PE species, indicating the PE-to PG conversion by *clsB*. The CL level is significantly increased upon *clsB* expression (data not shown).

***In Vivo and in Vitro* Synthesis of Phosphatidylglycerol by an *Escherichia coli* Cardiolipin Synthase**

Chijun Li, Brandon K. Tan, Jinshi Zhao and Ziqiang Guan

*J. Biol. Chem.* 2016, 291:25144-25153.

doi: 10.1074/jbc.M116.762070 originally published online October 19, 2016

---

Access the most updated version of this article at doi: [10.1074/jbc.M116.762070](https://doi.org/10.1074/jbc.M116.762070)

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts

Supplemental material:

<http://www.jbc.org/content/suppl/2016/10/19/M116.762070.DC1.html>

This article cites 39 references, 23 of which can be accessed free at

<http://www.jbc.org/content/291/48/25144.full.html#ref-list-1>